Evidence map›Paper›PMID 32185393›Full record

ArticleBrain : a journal of neurology2020

CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis.

Carol Dobson-Stone, Marianne Hallupp, Hamideh Shahheydari, Audrey M G Ragagnin, Zac Chatterton, Francine Carew-Jones, Claire E Shepherd, Holly Stefen, Esmeralda Paric, Thomas Fath and 28 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Ubiquitin-Proteasome System in Brain Disorders: Pathogenic Pathways, Post-Translational Tweaks, and Therapeutic Frontiers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  10. Article
  11. Review
  12. AKT and DUBs: a bidirectional relationship.Cellular & molecular biology letters · 2025
    Review
  13. Role of CYLD in brain physiology and pathology.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  14. Article
  15. Article
  16. Deubiquitinases in muscle physiology and disorders.Biochemical Society transactions · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 13 institutions in 3 countries.

Carol Dobson-StoneThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Marianne HalluppThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Hamideh ShahheydariCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Audrey M G RagagninCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Zac ChattertonThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Francine Carew-JonesNeuroscience Research Australia, Randwick, NSW 2031, Australia.
Claire E ShepherdNeuroscience Research Australia, Randwick, NSW 2031, Australia.
Holly StefenDementia Research Centre and Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Esmeralda ParicDementia Research Centre and Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Thomas FathDementia Research Centre and Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Elizabeth M ThompsonSA Clinical Genetics Service, Women's and Children's Hospital, North Adelaide 5006, SA, Australia.
Peter BlumbergsInstitute of Medical and Veterinary Science, Adelaide, SA 5000, Australia.
Cathy L ShortDepartment of Neurology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia.
Colin D FieldAdelaide Dementia Driving Clinic, Adelaide, SA 5041, Australia.
Peter K PanegyresNeurodegenerative Disorders Research Pty Ltd, West Perth, WA 6005, Australia.
Jane HeckerDepartment of General Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
Garth NicholsonNorthcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW 2137, Australia.
Alex D ShawThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Janice M FullertonNeuroscience Research Australia, Randwick, NSW 2031, Australia.
Agnes A LutyNeuroscience Research Australia, Randwick, NSW 2031, Australia.
Peter R SchofieldNeuroscience Research Australia, Randwick, NSW 2031, Australia.
William S BrooksNeuroscience Research Australia, Randwick, NSW 2031, Australia.
Neil RajanInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK.
Mark F BennettPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Melanie BahloPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
John E LandersUniversity of Massachusetts Medical School, Worcester, MA 01655, USA.
Olivier PiguetThe University of Sydney, Brain and Mind Centre and School of Psychology, Camperdown, NSW 2006, Australia.
John R HodgesThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Glenda M HallidayThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Simon D ToppUK Dementia Research Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London SE5 9RX, UK.
Bradley N SmithUK Dementia Research Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London SE5 9RX, UK.
Christopher E ShawUK Dementia Research Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London SE5 9RX, UK.
Emily McCannCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Jennifer A FifitaCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Kelly L WilliamsCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Julie D AtkinCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Ian P BlairCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
John B KwokThe University of Sydney, Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, Camperdown, NSW 2006, Australia.
Macquarie University · AUThe University of Sydney · AUUNSW Sydney · AUKing's College London · GBThe University of Melbourne · AUUniversity of Massachusetts Chan Medical School · USInstitute for Neurodegenerative Disorders · USLa Trobe University · AUNewcastle University · GBQueen Elizabeth Hospital · AURoyal Adelaide Hospital · AUSouth Australia Pathology · AUWomen's and Children's Hospital · AU

Funding

Identification of genes causative for familial ALS gene using exome sequencingR01NS073873 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANDERS, JOHN E · 2011 to 2019
$4.6M
Characterization of KIFAP3, a Modifier of Survival in Sporadic ALSR01NS065847 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANDERS, JOHN E · 2010 to 2014
$1.8M
Department of Health [UK]Motor Neurone Disease Association SMITH/APR16/847-791MRF_ MRF-060-0003-RG-SMITHNINDS NIH HHS R01 NS065847NINDS NIH HHS R01 NS073873Wellcome TrustWellcome Trust 100935/Z/13/ZWellcome Trust WT097163MA
6 · The paper itself

Abstract

Frontotemporal dementia and amyotrophic lateral sclerosis are clinically and pathologically overlapping disorders with shared genetic causes. We previously identified a disease locus on chromosome 16p12.1-q12.2 with genome-wide significant linkage in a large European Australian family with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosis and no mutation in known amyotrophic lateral sclerosis or dementia genes. Here we demonstrate the segregation of a novel missense variant in CYLD (c.2155A>G, p.M719V) within the linkage region as the genetic cause of disease in this family. Immunohistochemical analysis of brain tissue from two CYLD p.M719V mutation carriers showed widespread glial CYLD immunoreactivity. Primary mouse neurons transfected with CYLDM719V exhibited increased cytoplasmic localization of TDP-43 and shortened axons. CYLD encodes a lysine 63 deubiquitinase and CYLD cutaneous syndrome, a skin tumour disorder, is caused by mutations that lead to reduced deubiquitinase activity. In contrast with CYLD cutaneous syndrome-causative mutations, CYLDM719V exhibited significantly increased lysine 63 deubiquitinase activity relative to the wild-type enzyme (paired Wilcoxon signed-rank test P = 0.005). Overexpression of CYLDM719V in HEK293 cells led to more potent inhibition of the cell signalling molecule NF-κB and impairment of autophagosome fusion to lysosomes, a key process in autophagy. Although CYLD mutations appear to be rare, CYLD's interaction with at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral sclerosis genes (TBK1, OPTN and SQSTM1) suggests that it may play a central role in the pathogenesis of these disorders. Mutations in several frontotemporal dementia and amyotrophic lateral sclerosis genes, including TBK1, OPTN and SQSTM1, result in a loss of autophagy function. We show here that increased CYLD activity also reduces autophagy function, highlighting the importance of autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.

Indexed as

Amyotrophic Lateral SclerosisDeubiquitinating Enzyme CYLDFrontotemporal DementiaGenetic Predisposition to DiseaseAnimalsAutophagosomesAxonsBrainDeubiquitinating EnzymesDNA-Binding ProteinsHumansMiceMutation, MissenseNF-kappa BPrimary Cell CultureTransfectionCYLD protein, humanDeubiquitinating Enzyme CYLDDeubiquitinating EnzymesDNA-Binding ProteinsNF-kappa BTardbp protein, mouseautophagyCYLDdeubiquitinasegenome-wide linkage analysiswhole-exome sequencing

Identifiers

PMID32185393
PMCPMC7089666
OpenAlexW3011557986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.